Repligen board member Karen Dawes to retire after over 20 years
Dawes notified the company on September 10, 2026 that she will step down effective September 30, 2026, following the completion of a CEO transition.
SEC filing
Latest
3 stories
Tuesday, September 15
Tuesday, July 28
Repligen raises 2026 guidance after 13% organic revenue growth in Q2
The bioprocessing company also disclosed a definitive agreement to acquire BioLife Solutions as it lifted its full-year revenue and earnings outlook.
SEC filing
Wednesday, July 22
Repligen-BioLife merger agreement includes $59 million termination fee, January 2027 outside date
The newly filed merger agreement and 8-K detail deal mechanics, closing conditions, and termination terms for the $1.5 billion transaction announced July 22, 2026.
SEC filing